Sharekhan

Bliss GVS Pharma Ltd

Thu 10/07/2025,15:57:21 NSE: BLISSGVS

₹ 153.79 -2.18 (-1.40%)
BUY NOW Buy Bliss GVS Pharma Ltd Stock

Open Free Demat and Trading account in 15 minutes

Home Stock Bliss GVS Pharma Ltd

Thu 10/07/2025,16:1:0

Bliss GVS Pharma Ltd

Thu 10/07/2025,15:57:21 | NSE : BLISSGVS

₹ 153.79-2.18 (-1.40%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 156.49

Previous Close

₹ 155.97

Volume

352871

Mkt Cap ( Rs. Cr)

₹1622.45

High

₹ 158.05

Low

₹ 151.51

52 Week High

₹ 185.50

52 Week Low

₹ 106.04

Book Value Per Share

₹ 95.73

Dividend Yield

0.32

Face Value

₹ 1.00

What’s Your Call?

Collective community sentiment on Bliss GVS Pharma Ltd

Your Vote -

Buy

84.38%

Hold

9.38%

Sell

6.25%

84.38%

32 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

100%

Sell Order Quantity

0%

Bid Price

Qty

153.79

635

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

635

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Option Chain

Analyzes market sentiment, predicts Bliss GVS Pharma Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Bliss GVS Pharma - Business Responsibility and Sustainability Reporting (BRSR)

    9 Jul 2025, 8:45PM Please find enclosed herewith the Business Responsibility and Sustainability Report for the FY 2024-2025.

  • Bliss GVS Pharma - Notice Of The 40Th Annual General Meeting ('40Th AGM') Of Bliss GVS Pharma Limited

    9 Jul 2025, 8:28PM Please find enclosed herewith the Notice of the 40th AGM of Bliss GVS Pharma Limited (\the Company\) scheduled to be held on Thursday, July 31, 2025,

  • Bliss GVS Pharma - Reg. 34 (1) Annual Report.

    9 Jul 2025, 8:19PM Pursuant to Regulation 34(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI

  • Bliss GVS Pharma has declared 50% Final dividend for the financial year March 2025

    9 Jul 2025, 11:20AM Bliss GVS Pharma Ltd. on Monday, 12 May 2025, has announced Final dividend of 50 percent on Equity Share, to its shareholders holding shares on the re

  • Bliss GVS Pharma - Updates

    8 Jul 2025, 6:15PM Bliss GVS Pharma Limited has informed the Exchange regarding 'Intimation of Book Closure in accordance with Regulation 42 of the SEBI (Listing Obligat

  • Bliss GVS Pharma - Record Date

    8 Jul 2025, 6:12PM Bliss GVS Pharma Limited has informed the Exchange that Record date for the purpose of Dividend & Meeting is 24-Jul-2025.

  • Bliss GVS Pharma - Intimation Of Book Closure In Accordance With Regulation 42 Of The SEBI (Listing Obligations And Disclosur

    8 Jul 2025, 6:02PM Please find enclosed herewith the Intimation for Book Closure for the purpose of the 40th Annual General Meeting of the Company.

  • Bliss GVS Pharma - Intimation Of Record Date In Accordance With Regulation 42 Of The SEBI (Listing Obligations And Disclosure

    8 Jul 2025, 5:57PM Please find enclosed herewith the Intimation regarding Fixation of Record Date for the payment of Final Dividend for the financial year ended March 31

  • Bliss GVS Pharma - Communication To Shareholders - Intimation Of Tax Deduction On Dividend

    8 Jul 2025, 11:49AM Please find enclosed herewith the communication sent to shareholders regarding Intimation of Tax Deduction on Dividend.

  • Bliss GVS Pharma - Copy of Newspaper Publication

    8 Jul 2025, 11:42AM Bliss GVS Pharma Limited has informed the Exchange about a Copy of the Newspaper Publication regarding the Submission of the Newspaper Publication reg

  • Bliss GVS Pharma - General Updates

    8 Jul 2025, 11:40AM Bliss GVS Pharma Limited has informed the Exchange about Communication to Shareholders - Intimation of Tax Deduction on Dividend

  • Bliss GVS Pharma - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    4 Jul 2025, 7:15PM Please find enclosed the certificate received under Regulation 74(5) of SEBI (DP) Regulation 2018 for the quarter ended June 30, 2025.

  • Bliss GVS Pharma - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    4 Jul 2025, 7:11PM Bliss GVS Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

  • Bliss GVS Pharma - Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company

    2 Jul 2025, 5:17PM Bliss GVS Pharma Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company

  • Bliss GVS Pharma - Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosu

    2 Jul 2025, 5:11PM Please find attached the intimation regarding the Show Cause Notice issued by the Joint Commissioner of CGST and Central Excise, Mumbai.

  • Bliss GVS Pharma - Alteration Of Capital and Fund Raising-XBRL

    30 Jun 2025, 6:38PM BLISS GVS PHARMA LIMITED has informed the Exchange regarding Allotment of Securities

  • Bliss GVS Pharma - ESOP/ESOS/ESPS

    30 Jun 2025, 6:30PM Bliss GVS Pharma Limited has informed the Exchange regarding Allotment of 52000 Shares.

  • Bliss GVS Pharma - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    30 Jun 2025, 6:19PM We would like to inform you that the ESOP Allotment Committee at its meeting held on June 30, 2025, has approved the allotment of 52,000 equity shares

  • Bliss GVS Pharma - Copy of Newspaper Publication

    30 Jun 2025, 4:31PM Bliss GVS Pharma Limited has informed the Exchange about Copy of Newspaper Publication regarding Publication of Notice to Shareholders for Transfer of

  • Bliss GVS Pharma - Updates

    30 Jun 2025, 12:06PM Bliss GVS Pharma Limited has informed the Exchange regarding 'Notice to Shareholders w.r.t. transfer of unclaimed Final Dividend 2017-2018 and itsCorr

  • Bliss GVS Pharma - Trading Window-XBRL

    30 Jun 2025, 11:33AM BLISS GVS PHARMA LIMITED has informed the Exchange about Closure of Trading Window

  • Bliss GVS Pharma - Trading Window

    30 Jun 2025, 11:30AM Bliss GVS Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations,

  • Bliss GVS Pharma - Notice To Shareholders W.R.T. Transfer Of Unclaimed Final\r\nDividend 2017-2018 And Its Corresponding Shar

    30 Jun 2025, 12:01PM Please find enclosed herewith the Notice sent to the Shareholders of the Company w.r.t. Transfer of Unclaimed Final Dividend 2017-2018 and its corresp

  • Bliss GVS Pharma - Disclosure under SEBI Takeover Regulations

    18 Jun 2025, 6:50PM Bliss GVS Pharma Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Subs

  • Bliss GVS Pharma - Disclosure under SEBI Takeover Regulations

    18 Jun 2025, 6:06PM Bliss GVS Pharma Limitedÿhas Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Subs

  • Bliss GVS Pharma - Shareholders meeting

    12 Jun 2025, 3:42PM Bliss GVS Pharma Limited has submitted to the Exchange a copy of the Scrutinizers' report of the Postal Ballot, along with the Voting Results.

  • Bliss GVS Pharma - Shareholder Meeting / Postal Ballot-Scrutinizer\s Report

    12 Jun 2025, 4:09PM In connection with the Postal Ballot Notice dated May 12, 2025, please find enclosed herewith the outcome of the Postal ballot along with the Scrutini

  • Bliss GVS Pharma - Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot

    12 Jun 2025, 4:05PM In connection with the Postal Ballot Notice dated May 12, 2025, please find enclosed herewith the outcome of the Postal Ballot along with the Scrutini

  • Bliss GVS Pharma - Update On Legal Proceeding

    23 May 2025, 4:25PM Enclosed herewith please find attached an update on the legal proceeding - Commercial Suit for Infringement of Intellectual Property Rights.

  • Bliss GVS Pharma - Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company

    23 May 2025, 4:00PM Bliss GVS Pharma Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company

  • Bliss GVS Pharma - Copy of Newspaper Publication

    14 May 2025, 3:09PM Bliss GVS Pharma Limited has informed the Exchange about Copy of the Newspaper Publication regarding the Audited Standalone and Consolidated Financial

  • Bliss GVS Pharma - Sale or disposal-XBRL

    13 May 2025, 6:00PM BLISS GVS PHARMA LIMITED has informed the Exchange regarding Sale or disposal of unit(s)/division(s)/subsidiary

  • Bliss GVS Pharma - Alteration Of Capital and Fund Raising-XBRL

    13 May 2025, 5:35PM BLISS GVS PHARMA LIMITED has informed the Exchange regarding Issuance of securities

  • Bliss GVS Pharma - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent

    13 May 2025, 3:42PM BLISS GVS PHARMA LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Ag

  • Bliss GVS Pharma - Notice Of Shareholders Meetings-XBRL

    13 May 2025, 3:22PM BLISS GVS PHARMA LIMITED has informed the Exchange about Notice of Shareholders Meeting for Postal Ballot

  • Bliss GVS Pharma - Outcome of Board Meeting-XBRL

    13 May 2025, 3:20PM BLISS GVS PHARMA LIMITED has informed the Exchange regarding Outcome of Board Meeting held on 12-May-2025 for Dividend

  • Bliss GVS Pharma - Copy of Newspaper Publication

    13 May 2025, 1:31PM Bliss GVS Pharma Limited has informed the Exchange about Copy of Newspaper Publication regarding dispatch of Postal Ballot Notice.

  • Bliss GVS Pharma - Outcome of Board Meeting

    12 May 2025, 11:03PM Bliss GVS Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on May 12, 2025.

  • Bliss GVS Pharma - Grant Of Options Under Bliss GVS Pharma Limited - Employee Stock Options Plan 2019

    12 May 2025, 10:18PM Grant of 8,62,000 Stock Option under Bliss GVS Pharma Limited- Employee Stock Option Plan 2019

  • Bliss GVS Pharma - Announcement under Regulation 30 (LODR)-Change in Management

    12 May 2025, 10:04PM Appointment of Internal Auditor and Secretarial Auditor.

  • Bliss GVS Pharma - Options to purchase securities

    12 May 2025, 9:57PM Bliss GVS Pharma Limited has informed the Exchange about Options to purchase securities

  • Bliss GVS Pharma - Integrated Filing (Financial)

    12 May 2025, 9:53PM Integrated Filing (Financial) for the quarter and year ended March 31, 2025.

  • Bliss GVS Pharma - Change in Auditors

    12 May 2025, 9:52PM Bliss GVS Pharma Limited has informed the Exchange regarding Change in Auditors of the company.

  • Bliss GVS Pharma posts Q4 net profit of Rs 11.45 cr

    12 May 2025, 9:50PM The company reported standalone net profit during the quarter stood at Rs 11.45 crore compared to net loss of Rs 11.46 crore in the previous year quar

  • Bliss GVS Pharma - Updates

    12 May 2025, 9:38PM Bliss GVS Pharma Limited has informed the Exchange regarding 'Intimation of Book Closure for 40th AGM'.

  • Bliss GVS Pharma - Dividend

    12 May 2025, 9:35PM Bliss GVS Pharma Limited has informed the Exchange that Board of Directors at its meeting held on May 12, 2025, recommended Final Dividend of 0.50 per

  • Bliss GVS Pharma - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

    12 May 2025, 9:33PM Notice of Postal Ballot dated May 12, 2025.

  • Bliss GVS Pharma - Shareholders meeting

    12 May 2025, 9:32PM Bliss GVS Pharma Limited has informed the Exchange regarding Notice of Postal Ballot

  • Bliss GVS Pharma - Intimation Of Book Closure In Accordance With Regulation 42 Of SEBI (Listing Obligations And Disclosure Re

    12 May 2025, 9:25PM According to Section 91 of the Companies Act, 2013 and Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (

  • Bliss GVS Pharma - Corporate Action-Board approves Dividend

    12 May 2025, 9:10PM Declaration of Final Dividend for the Financial Year Ended March 31, 2025.

  • Bliss GVS Pharma - Outcome of Board Meeting

    12 May 2025, 9:06PM Bliss GVS Pharma Limited has informed the Exchange regarding Board meeting held on May 12, 2025.

  • Bliss GVS Pharma - Board Meeting Outcome for Outcome Of The Board Meeting Held On May 12, 2025.

    12 May 2025, 9:01PM We would like to inform you that, the Board Meeting of the Company was held today i.e. Monday, May 12, 2025 at the registered office of the Company. I

  • Bliss GVS Pharma - Issue of Securities

    12 May 2025, 7:12PM Bliss GVS Pharma Limited has informed the Exchange that the Board of Directors at its meeting held today i.e. Monday, May 12, 2025 has approved the is

  • Bliss GVS Pharma - Announcement under Regulation 30 (LODR)-Issue of Securities

    12 May 2025, 7:10PM The Board of Directors in its meeting held today i.e., May 12, 2025, has approved the issuance and allotment of Sweat Equity shares to the members of

  • Bliss GVS Pharma - Update on board meeting

    7 May 2025, 6:30PM Bliss GVS Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/05/2025 ,inter alia, to consider and

  • Bliss GVS Pharma - Board Meeting Intimation

    7 May 2025, 6:22PM BLISS GVS PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 12-May-2025 to consider Other business.

  • Bliss GVS Pharma - Board Meeting Intimation for Approval Of Audited (Standalone & Consolidated) Financial Results Of The Comp

    5 May 2025, 7:51PM Bliss GVS Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/05/2025 ,inter alia, to consider and

  • Bliss GVS Pharma - Board Meeting Intimation

    5 May 2025, 7:40PM BLISS GVS PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 12-May-2025 to consider and approve the Yearly Audited Financial

  • Bliss GVS Pharma - Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company

    3 May 2025, 10:34AM Bliss GVS Pharma Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company

  • Bliss GVS Pharma - Intimation Under Regulation 30 Of SEBI (LODR) Regulation, 2015- Pendency Of Litigation(S)/Dispute(S)\r\n

    3 May 2025, 10:26AM Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like

  • Bliss GVS Pharma - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

    30 Apr 2025, 12:07PM <b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border='1px'><tr> <td><b>Sr. No.</b></td

  • Bliss GVS Pharma - Intimation Of Change In Contact Details Of MUFG Intime India Private Limited, Registrar And Share Transfer

    22 Apr 2025, 6:24PM Please find attached the Intimation regarding change in contact details of MUFG Intime Private Limited (Formerly known as Link Intime India Private Li

  • Bliss GVS Pharma - Updates

    22 Apr 2025, 6:16PM Bliss GVS Pharma Limited has informed the Exchange regarding 'Intimation of change in contact details of MUFG Intime India Private Limited, Registrar

  • Bliss GVS Pharma has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2025

    16 Apr 2025, 5:42PM As of March 2025, 35.29% is owned by Indian Promoters and 64.71% by Public. <p align=justify> Institutional holds 19.73% (Insurance Companies 6.55%) a

  • Bliss GVS Pharma - Updates

    15 Apr 2025, 3:20PM Bliss GVS Pharma Limited has informed the Exchange regarding 'Intimation under Regulation 30 of SEBI (LODR) Regulation, 2015, we would like to inform

  • Bliss GVS Pharma - Intimation Under Regulation 30 Of SEBI (LODR) Regulation, 2015.

    15 Apr 2025, 3:31PM Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, we would like to inform you that the Rising Pharma Holdings, Inc. USA, a marketing and dis

  • Bliss GVS Pharma - Pendency Of Litigation(S)/Dispute(S)

    12 Apr 2025, 6:30PM This is a continuation of our communication dated March 26, 2021, regarding the commercial suit for infringement of Intellectual Property Rights. We p

  • Bliss GVS Pharma - Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company

    12 Apr 2025, 6:09PM Bliss GVS Pharma Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company

  • Bliss GVS approves to increase FII investment limit

    26 Feb 2019 , 10:09AM Board approves to increase the FPI/FII investment limit in the company

  • Bliss GVS board to consider disinvestment; stk up

    5 Jan 2018 , 12:01PM Bliss GVS board to meet on Jan 11, for considering disinvestment of subsidiary business
Load More
Show Less

Key fundamentals

Evaluate the intrinsic value of Bliss GVS Pharma Ltd stock 

Name March-25 March-24 March-23 March-22 March-21
Assets 1109.642 1054.0754 1014.0767 937.0434 823.5159
Liabilities 1109.642 1054.0754 1014.0767 937.0434 823.5159
Equity 10.537 10.4691 10.4153 10.3678 10.3147
Gross Profit 91.5856 107.1687 90.1552 109.199 91.4603
Net Profit 68.9687 50.6449 85.4786 92.664 67.5008
Cash From Operating Activities 97.2054 125.9225 43.8057 114.0494 66.9672
NPM(%) 10.33 8.36 14.28 14.56 14.5
Revenue 667.2046 605.4597 598.3395 636.3567 465.5131
Expenses 575.619 498.291 508.1843 527.1577 374.0528
ROE(%) 6.82 5.01 8.46 9.17 6.68

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
24 Jul 2025 0.5 50 0.33 118.77
18 Jul 2024 0.5 50 0.33 119.05
12 Jul 2023 0.5 50 0.33 83.8
20 Jun 2022 0.5 50 0.33 79
13 Sep 2021 0.5 50 0.33 128.1
17 Sep 2020 0.5 50 0.33 102.35
1 100 0.33 173.6
14 Aug 2018 1 100 0.33 196.65
18 Sep 2017 0.6 60 0.33 177.2
0.5 50 0.33 95.2
08 Sep 2015 0.5 50 0.33 122.45
24 Feb 2015 0.2 20 0.33 110.9
13 Aug 2014 0.5 50 0.33 43.8
01 Aug 2013 0.4 40 0.33 28.6
25 Feb 2013 0.3 30 0.33 36.5
02 Aug 2012 0.4 40 0.33 23
24 Nov 2011 0.35 35 0.33 23.7
14 Jul 2011 0.3 30 0.33 22.5
25 Nov 2010 0.3 30 0.33 44.75

Peers

Other companies within the same industry or sector that are comparable to Bliss GVS Pharma Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 903.30 -1.95 29.97 88.69 301.39 0.55
Lotus Eye Hospital and Institute Ltd 73.89 0.05 211.11 323.17 3.55 0.00
Vaishali Pharma Ltd 12.79 0.24 213.17 166.58 3.13 0.00
Astec Lifesciences Ltd 898.30 -1.72 0.00 304.76 -601.21 0.00

Company Info

1984 - Bliss GVS Pharma Limited was incorporated on 11th December, as public limited company and promoted by Mr Gautam Ashra. The company operates in two segments, health care products and pharma products. 2004 - Public shareholders of the company received an open offer by the Fedex Securities Ltd on behalf of Shri M G Wagle, Shri Gautam R Ashra & Shri Shibroor N Kamath. 2005 - Board of directors of the company had recommended the issue of bonus shares of 2 shares for every 5 shares. 2006 -Board of directors of the company on 9th May, 2006, had approved to takeover GVS Lab and to change the name of the company from 'Bliss Chemicals & Pharmaceuticals India Ltd' to 'Bliss GVS Pharma Ltd'. - Gautam Ashra, promoter director of the company, on 18th December 2006, sold 104,200 equity shares of the company for average sale price of Rs. 52.02 at the exchange. -Company has changed its name from Bliss Chemicals & Pharmaceuticals India Ltd. to Bliss GVS Pharma Ltd. 2007 - The board of the company had approved on 15th Jan 2007, to take over GVS Labs of S N Kamath for a consideration of Rs 160 million. The entire consideration will be paid by way of issue of 2,666,667 shares on a preferential basis to Kamath at a price of Rs 60 each (at a premium of Rs. 50 each). The takeover of GVS Lab was effective from Apr. 01, 2006. - The company had received an order of Rs. 25.00 crores for supply of Anti malarial Drugs for African Countries on November 2007. - The company set up its new manufacturing unit for tablets, dry syrup, oral suspension and suppository pessaries in the existing manufacturing facility at Palghar in Maharashtra. 2008 - Members at the extra ordinary general meeting of the company had approved split of shares of face Value of Rs 10 each into face value of Rs 1 each. -The company had fixed 18th March 2008 as the record date for the split of the equity shares of the company. The equity shares of face value Rs. 10 each will be sub divided in to face value of Rs. 1 each. -The Company has issued Bonus Shares in the Ratio of 3:5. 2009 -Company has received an Award from Pharmexcil -Company successfully completed its 25th year of operations. 2010 -Company has signed a Joint Venture Agreement with Kuwait -Mr. S N. Kamath, Promoter & Managing Director of the company has received a "National Award -2009 from Government of India in recognition outstanding performance Entrepreneurship under Medium Enterprises". -Registered Office of the Company has been shifted from 6/29-A, Udit Mittal Industry, Andheri Kurla Road, Andheri - East, Mumbai - 400 059 to 102, Hyde Park, Sakivihar Road, Andheri - East, Mumbai - 400 072 2011 -Bliss GVS Pharma Ltd recommended of 30% Dividend i.e. Rs. 0.30 per equity share 2012 -Company has acquired 70% management stake in the Company M/s. Kremoint Pharma Private Limited 2013 -Bliss GVS Pharma Ltd recommended a dividend of 40%. -Bliss GVS receives recognition for its Research & Development Lab from the Department of Scientific & Industrial Research (DSIR), Government of India. 2014 -Bliss GVS is named in Moneylife magazine's 'Wealth Creators 2004-2013' list, an annual study of companies that have created the maximum wealth for investors over the past 10 years. -Bliss GVS Wins - Outstanding Exports Award. 2015 -Bliss GVS Pharma wins Healthcare Services contract in Kenya 2016 -Bliss GVS Pharma arm wins $111 mn contract from Kenyan firm.

1984 - Bliss GVS Pharma Limited was incorporated on 11th December, as public limited company and promoted by Mr Gautam Ashra. The company operates in two segments, health care products and pharma products. 2004 - Public shareholders of the company received an open offer by the Fedex Securities Ltd on behalf of Shri M G Wagle, Shri Gautam R Ashra & Shri Shibroor N Kamath. 2005 - Board of directors of the company had recommended the issue of bonus shares of 2 shares for every 5 shares. 2006 -Board of directors of the company on 9th May, 2006, had approved to takeover GVS Lab and to change the name of the company from 'Bliss Chemicals & Pharmaceuticals India Ltd' to 'Bliss GVS Pharma Ltd'. - Gautam Ashra, promoter director of the company, on 18th December 2006, sold 104,200 equity shares of the company for average sale price of Rs. 52.02 at the exchange. -Company has changed its name from Bliss Chemicals & Pharmaceuticals India Ltd. to Bliss GVS Pharma Ltd. 2007 - The board of the company had approved on 15th Jan 2007, to take over GVS Labs of S N Kamath for a consideration of Rs 160 million. The entire consideration will be paid by way of issue of 2,666,667 shares on a preferential basis to Kamath at a price of Rs 60 each (at a premium of Rs. 50 each). The takeover of GVS Lab was effective from Apr. 01, 2006. - The company had received an order of Rs. 25.00 crores for supply of Anti malarial Drugs for African Countries on November 2007. - The company set up its new manufacturing unit for tablets, dry syrup, oral suspension and suppository pessaries in the existing manufacturing facility at Palghar in Maharashtra. 2008 - Members at the extra ordinary general meeting of the company had approved split of shares of face Value of Rs 10 each into face value of Rs 1 each. -The company had fixed 18th March 2008 as the record date for the split of the equity shares of the company. The equity shares of face value Rs. 10 each will be sub divided in to face value of Rs. 1 each. -The Company has issued Bonus Shares in the Ratio of 3:5. 2009 -Company has received an Award from Pharmexcil -Company successfully completed its 25th year of operations. 2010 -Company has signed a Joint Venture Agreement with Kuwait -Mr. S N. Kamath, Promoter & Managing Director of the company has received a "National Award -2009 from Government of India in recognition outstanding performance Entrepreneurship under Medium Enterprises". -Registered Office of the Company has been shifted from 6/29-A, Udit Mittal Industry, Andheri Kurla Road, Andheri - East, Mumbai - 400 059 to 102, Hyde Park, Sakivihar Road, Andheri - East, Mumbai - 400 072 2011 -Bliss GVS Pharma Ltd recommended of 30% Dividend i.e. Rs. 0.30 per equity share 2012 -Company has acquired 70% management stake in the Company M/s. Kremoint Pharma Private Limited 2013 -Bliss GVS Pharma Ltd recommended a dividend of 40%. -Bliss GVS receives recognition for its Research & Development Lab from the Department of Scientific & Industrial Research (DSIR), Government of India. 2014 -Bliss GVS is named in Moneylife magazine's 'Wealth Creators 2004-2013' list, an annual study of companies that have created the maximum wealth for investors over the past 10 years. -Bliss GVS Wins - Outstanding Exports Award. 2015 -Bliss GVS Pharma wins Healthcare Services contract in Kenya 2016 -Bliss GVS Pharma arm wins $111 mn contract from Kenyan firm.

Read More

Parent Organisation

Bliss GVS Pharma Ltd.

Founded

11/12/1984

Managing Director

Mr.Gagan Harsh Sharma

NSE Symbol

BLISSGVSEQ

FAQ

The current price of Bliss GVS Pharma Ltd is ₹ 153.79.

The 52-week high for Bliss GVS Pharma Ltd is ₹ 158.05 and the 52-week low is ₹ 151.51.

The market capitalization of Bliss GVS Pharma Ltd is currently ₹ 1622.45. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Bliss GVS Pharma Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Bliss GVS Pharma Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Bliss GVS Pharma Ltd shares.

The CEO of Bliss GVS Pharma Ltd is Mr.Gagan Harsh Sharma, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT